Skip to contentF
Fulcrum Therapeutics, Inc.
F
FULCFulcrum Therapeutics, Inc. Q3 2025 · 10-Q
Revenue$0.00$0.00— vs Q3 2024 Net Income-$19.60M-$19.60MN/M vs Q3 2024 EPS Diluted-$0.31-$0.31N/M vs Q3 2024 Operating Income-$21,858,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$14,280,000N/M ended Sep 30, 2025 · filed Oct 29, 2025 · 29 d after period end